<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2659">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340466</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00797-32</org_study_id>
    <nct_id>NCT04340466</nct_id>
  </id_info>
  <brief_title>French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study</brief_title>
  <acronym>FRENCH CORONA</acronym>
  <official_title>French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from
      China to other countries causing an international outbreak of respiratory illnesses named
      COVID-19. In France, the first cases have been reported at the end of January with more than
      60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19
      patients will be admitted to intensive care unit. However, few data are available for this
      special population in France.

      We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that
      will enable to describe the initial management of COVID 19 patients admitted to ICU and to
      identify factors correlated to clinical outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>Mortality at day 28</measure>
    <time_frame>day 28</time_frame>
    <description>Mortality at day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severe complications</measure>
    <time_frame>up to day 28</time_frame>
    <description>severe complications (pulmonary embolism, acute kidney injury, myocarditis, cardiac arrest, liver failure, ventilator associated pneumonia) Yes / No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging</measure>
    <time_frame>day 1</time_frame>
    <description>Delay in imaging in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay in Microbiological diagnosis</measure>
    <time_frame>day 1</time_frame>
    <description>delay in microbiological diagnosis in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral therapy</measure>
    <time_frame>up to day 28</time_frame>
    <description>Antiviral therapy Yes / no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic therapy</measure>
    <time_frame>day 28</time_frame>
    <description>Antibiotic therapy Yes / No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covid-19 treatments</measure>
    <time_frame>up to day 28</time_frame>
    <description>Covid-19 treatments Yes / No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients receiving renal replacement therapy</measure>
    <time_frame>up to day 28</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients receiving mechanical ventilation</measure>
    <time_frame>up to day 28</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status</measure>
    <time_frame>day 28</time_frame>
    <description>Patient alive at day 28 : yes / No</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Pneumonia, Viral</condition>
  <condition>Critically Ill</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Suspected or proven COVID-19 critically ill patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Suspected or proven COVID-19 critically ill patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population of the study is all patients with suspected or proven SARS-Cov-2
        infection (COVID-19)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to ICU for suspected or proven SARS-Cov-2 infection, defined by
             positive SARS-Cov-2 PCR or CT scan images

          -  Patient &gt; or= 18 years

        Exclusion Criteria:

          -  Patient study refusal

          -  Patient already enrolled in the present study

          -  Patient with respiratory illness with negative COVID-19 CT scan images and negative
             COVID_19 PCR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CLAIRE ROGER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nimes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CLAIRE ROGER, MD, PhD</last_name>
    <phone>0033466683050</phone>
    <email>claire.roger@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anissa MEGZARI</last_name>
    <email>drc@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Roger, MD, PhD</last_name>
      <phone>+33466683331</phone>
      <email>claire.roger@chu-nimes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-Cov-2</keyword>
  <keyword>Intensive Care Unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

